← Leaderboards
Geoffrey I Shapiro
Dana-Farber Cancer Inst
$18,639,470
Attributed
$35,699,321
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$45,164,770 · 13
By mechanism
UM1$23,631,028 · 1
P50$12,058,274 · 5
R01$8,092,427 · 3
P01$1,021,920 · 1
P30$361,121 · 3
Top collaborators
- Keith T Flaherty13 shared
- Donald W. Kufe13 shared
- Nancy U Lin4 shared
- Kornelia Polyak4 shared
- Christopher A French3 shared
- Derin B Keskin3 shared
- Leif W Ellisen1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Rochelle Bagatell$1,843,838
- Derin B Keskin$4,214,235
- Michael L. Cheng$463,885
- Donald W. Kufe$50,160,456
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsClinical TrialsTumorPharmacodynamicsMalignant NeoplasmsResponseResistancePre-ClinicalCancer CenterBiological MarkersResearch PersonnelCellsMediatingProgramsDesignCell LineTranslatingDrug KineticsDana-Farber Cancer InstituteDna RepairMentorsInhibitor/AntagonistBaseBiopsy
Grant awards (56)
Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer$2,607,297
P50 · FY2025 · CA
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$2,074,014
UM1 · FY2025 · CA · contact PI
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers$795,857
R01 · FY2025 · CA · contact PI
Genetically engineered mouse model to improve therapy of NUT carcinoma$657,032
R01 · FY2025 · CA
Pathology Core$590,984
P01 · FY2025 · CA · contact PI
Project 4: Combined targeting of DNA repair and macrophage-mediated immunosuppression in BRCA1/2-associated breast cancer$346,781
P50 · FY2025 · CA · contact PI
DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN$194,240
UM1 · FY2025 · CA · contact PI
Program 12: Developmental Therapeutics$46,974
P30 · FY2025 · CA · contact PI
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$1,970,313
UM1 · FY2024 · CA · contact PI
Genetically engineered mouse model to improve therapy of NUT carcinoma$629,248
R01 · FY2024 · CA
Pathology Core$430,936
P01 · FY2024 · CA · contact PI
ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)$393,712
P50 · FY2024 · CA · contact PI
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers$377,516
R01 · FY2024 · CA · contact PI
Program 12: Developmental Therapeutics$40,758
P30 · FY2024 · CA · contact PI
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$2,555,380
UM1 · FY2023 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer$2,302,230
P50 · FY2023 · CA
Genetically engineered mouse model to improve therapy of NUT carcinoma$672,468
R01 · FY2023 · CA
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers$389,092
R01 · FY2023 · CA · contact PI
ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)$352,737
P50 · FY2023 · CA · contact PI
Program 12: Developmental Therapeutics$42,116
P30 · FY2023 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer$2,210,645
P50 · FY2022 · CA
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers$414,529
R01 · FY2022 · CA · contact PI
ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)$377,448
P50 · FY2022 · CA · contact PI
Program 12: Developmental Therapeutics$42,116
P30 · FY2022 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer$2,345,277
P50 · FY2021 · CA
ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)$354,796
P50 · FY2021 · CA · contact PI
XPO1 inhibitors Selinexor and Eltanexor in Combination with Venetoclax and Decitabine (ASTX727) in AML$124,999
UM1 · FY2021 · CA · contact PI
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center$100,000
UM1 · FY2021 · CA · contact PI
Program 12: Developmental Therapeutics$93,161
P30 · FY2021 · CA · contact PI
DanaâFarber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$6,942,412
UM1 · FY2020 · CA · contact PI
ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)$412,977
P50 · FY2020 · CA · contact PI
Program 12: Developmental Therapeutics$93,048
P30 · FY2020 · CA · contact PI
Program 12: Developmental Therapeutics$2,948
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$2,325,303
UM1 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,952,701
UM1 · FY2018 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,765,337
UM1 · FY2016 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$713,143
UM1 · FY2016 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,513,183
UM1 · FY2015 · CA
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,400,003
UM1 · FY2014 · CA
Cyclin-Dependent Kinase Inhibition During S Phase$296,988
R01 · FY2014 · CA · contact PI
Cyclin-Dependent Kinase Inhibition During S Phase$82,084
R01 · FY2014 · CA · contact PI
Cyclin-Dependent Kinase Inhibition During S Phase$287,802
R01 · FY2013 · CA · contact PI
Cyclin-Dependent Kinase Inhibition During S Phase$51,552
R01 · FY2013 · CA · contact PI
Cyclin-Dependent Kinase Inhibition During S Phase$306,173
R01 · FY2012 · CA · contact PI
Cyclin-Dependent Kinase Inhibition During S Phase$306,173
R01 · FY2011 · CA · contact PI
Cyclin-Dependent Kinase Inhibition During S Phase$332,325
R01 · FY2010 · CA · contact PI
Translational studies of Hsp90 inhibitors in NSCLC$195,254
P50 · FY2009 · CA · contact PI
Flavopiridol Mediated Apoptosis During S Phase$313,185
R01 · FY2008 · CA · contact PI
Translational studies of Hsp90 inhibitors in NSCLC$159,120
P50 · FY2008 · CA · contact PI
Flavopiridol Mediated Apoptosis During S Phase$313,185
R01 · FY2007 · CA · contact PI
Flavopiridol Mediated Apoptosis During S Phase$322,538
R01 · FY2006 · CA · contact PI
Flavopiridol Mediated Apoptosis During S Phase$330,300
R01 · FY2005 · CA
Flavopiridol Mediated Apoptosis During S Phase$330,300
R01 · FY2004 · CA
Flavopiridol Mediated Apoptosis During S Phase in NSCLC$294,120
R01 · FY2003 · CA
Flavopiridol Mediated Apoptosis During S Phase in NSCLC$294,550
R01 · FY2002 · CA
Flavopiridol Mediated Apoptosis During S Phase in NSCLC$295,410
R01 · FY2001 · CA